Please assess the completion status of the following clinical trial:

Trial Title: International Immune Tolerance Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe hemophilia A (FVIII level \<1%).~* A maximum historical inhibitor titer of between 5 BU and 200 BU that must be confirmed once prior to the beginning of ITI.~* The inhibitor titer should be \<10 BU at the start of ITI, confirmed once.~* The inhibitor must be present for \<24 months when ITI begins.~* Maximum age of 7 at the start of ITI.~* Willingness to comply with the protocol.~Exclusion Criteria:~* Moderate or mild hemophilia A (FVIII level \>1%).~* Spontaneous disappearance of the inhibitor prior to ITI.~* Historical maximum inhibitor titer \<5 BU or \> 200 BU before starting ITI.~* Inhibitor titer \> 10 BU at the start of ITI.~* Inhibitor present for more than 24 months before starting ITI.~* Systemic immunomodulatory drug therapy during immune tolerance e.g. corticosteroids (\< 5 days every 2 months maximum dose 2 mg/kg or 60 mg/day), azathioprine, cyclophosphamide, high-dose immunoglobulin or the use of a protein A column or plasmapheresis.~* Age \> 7 years at the start of ITI.~* Inability or unwillingness to comply with the protocol.~* Previous attempt at ITI.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Low-dose treatment (50 FVIII u/kg three times a week).
- 2 (Type: ACTIVE_COMPARATOR): High-dose treatment (200 FVIII u/kg per day).

Based on this trial design, predict the completion outcome and termination type (if applicable).